Barely Significant
← all excerpts

First-Line MET Tyrosine Kinase Inhibitors versus Immunotherapy ± Chemotherapy for Patients with MET Exon 14 Skipping Mutant Metastatic NSCLC.

Clin Cancer Res · 2025 · PMC12616240 · PMID 40864503

Europe PMCDOI
1
hedged sentence
0.0700
closest p · 1.4× alpha
0.0700
boldest claim

The sentences

did not reach statistical significanceP = 0.07so close (0.05 < p ≤ 0.1)
A numerically longer OS was observed with ICI ± chemotherapy compared with MET TKI, although this did not reach statistical significance (43.8 vs. 15.8 months; HR, 0.52; 95% CI, 0.26–1.04; P = 0.07; Fig. 3A–C ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.